Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Davenport

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pharmacology|December 11, 2014
Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadolineJ Michael Davenport, Paul Covington, Laura Bonifacio, et al.
Plos One|July 26, 2012
TH17, TH22 and Treg cells are enriched in the healthy human cecumMartin J Wolff, Jacqueline M Leung, Michael Davenport, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2011
Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infectionPaul Covington, J Michael Davenport, David Andrae, et al.
Journal of Neurotrauma|January 25, 2006
Combined treatment with neurotrophin-3 and LSD facilitates behavioral recovery from double-hemisection spinal injury in neonatal ratsVictor L Arvanian, Honeyleen Manuzon, Michael Davenport, et al.
Optics Express|February 9, 2019
Heterogeneous silicon photonics sensing for autonomous carsWeiqiang Xie, Tin Komljenovic, Jinxi Huang, et al.
Clinical Therapeutics|April 15, 2008
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjectsRonald Christopher, Paul Covington, Michael Davenport, et al.
Clinical Therapeutics|April 15, 2008
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetesPaul Covington, Ronald Christopher, Michael Davenport, et al.
Nature Reviews. Urology|March 2, 2017
New and developing diagnostic technologies for urinary tract infectionsMichael Davenport, Kathleen E Mach, Linda M Dairiki Shortliffe, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2J Michael Davenport, Paul Covington, Mark Gotfried, et al.
Aesthetic Surgery Journal|September 4, 2012
Aesthetic and functional satisfaction after monsplasty in the massive weight loss populationJacob M P Bloom, Emily Van Kouwenberg, Michael Davenport, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|December 11, 2014
Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadolineJ Michael Davenport, Paul Covington, Laura Bonifacio, et al.
Plos One|July 26, 2012
TH17, TH22 and Treg cells are enriched in the healthy human cecumMartin J Wolff, Jacqueline M Leung, Michael Davenport, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2011
Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infectionPaul Covington, J Michael Davenport, David Andrae, et al.
Journal of Neurotrauma|January 25, 2006
Combined treatment with neurotrophin-3 and LSD facilitates behavioral recovery from double-hemisection spinal injury in neonatal ratsVictor L Arvanian, Honeyleen Manuzon, Michael Davenport, et al.
Optics Express|February 9, 2019
Heterogeneous silicon photonics sensing for autonomous carsWeiqiang Xie, Tin Komljenovic, Jinxi Huang, et al.
Clinical Therapeutics|April 15, 2008
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjectsRonald Christopher, Paul Covington, Michael Davenport, et al.
Clinical Therapeutics|April 15, 2008
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetesPaul Covington, Ronald Christopher, Michael Davenport, et al.
Nature Reviews. Urology|March 2, 2017
New and developing diagnostic technologies for urinary tract infectionsMichael Davenport, Kathleen E Mach, Linda M Dairiki Shortliffe, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Summary of Pharmacokinetics and Tissue Distribution of a Broad-Spectrum Fluoroquinolone, JNJ-Q2J Michael Davenport, Paul Covington, Mark Gotfried, et al.
Aesthetic Surgery Journal|September 4, 2012
Aesthetic and functional satisfaction after monsplasty in the massive weight loss populationJacob M P Bloom, Emily Van Kouwenberg, Michael Davenport, et al.
Pageof 3